TRANBERG Thermal Therapy System developer Clinical Laserthermia Systems AB (publ) (STO:CLS-B) announced on Thursday that it has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT), a medical device company, valued at approximately SEK7.5m.
These orders are for ClearPoint Prism products as part of ClearPoint Neuro's North American market launch initiated in early June this year. This follows previous orders totaling approximately SEK10.5m received around the turn of the year 2023/2024.
CLS and ClearPoint Neuro aim to develop and commercialize a next-generation, fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation in neurosurgery. The integrated product solution offers streamlined workflows for identifying, navigating and positioning sterile laser applicators in target tissues, with MRI-guided monitoring and control of temperature and ablation progress.
Recent strategic steps include obtaining US-FDA 510(k) clearance for ClearPoint Neuro's Prism Bone Anchor Accessory, further strengthening the product offering and expanding the market in the US.
(EUR1=SEK11.19)
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15